Evofem Biosciences, INC 8-K filings

Evofem Biosciences has received notice from OTC Markets Group that it is not in compliance with the minimum bid price requirement for continued listing on the OTCQB Venture Market.

Evofem Biosciences and Aditxt have amended their merger agreement, pushing back a key funding date to either September 6, 2024, or shortly after Aditxt completes a $20 million public offering.

Evofem Biosciences announced improved financial results for the second quarter of 2024, highlighted by a significant reduction in operating losses and increased net sales.

Evofem Biosciences has granted Pharma 1 exclusive rights to commercialize Phexxi in the Middle East, including the UAE, Kuwait, Saudi Arabia, and Qatar.

Evofem Biosciences has acquired Lupin's U.S. women's health specialty business, including the drug SOLOSEC, for a potential total consideration of up to $84 million.

Evofem Biosciences has entered into an amended merger agreement with Aditxt, Inc., outlining the terms of their business combination.

Evofem Biosciences has released a corporate slide presentation to update the investment community on its business.

Evofem Biosciences has amended the terms of its Series F-1 Convertible Preferred Stock, including a reduction in the conversion price to $0.0154 per share.

Evofem Biosciences announced its first quarter 2024 financial results, showing a decrease in net sales but improved operating losses and strategic advancements.

Evofem Biosciences has reinstated its merger agreement with Aditxt after a prior termination, securing a $1 million initial payment and amending terms for future capital raises.

Evofem Biosciences has released a new corporate slide presentation to update the investment community on its business.

Evofem Biosciences announced a significant increase in Phexxi net product sales and a substantial reduction in operating expenses for 2023, alongside a planned acquisition by Aditxt, Inc.

Evofem Biosciences and Aditxt have amended their merger agreement, extending the proxy filing deadline and replacing a loan requirement with a $3.5 million equity investment.

Evofem Biosciences announced strong preliminary 2023 results, including record net sales for Phexxi and a significant reduction in operating expenses.

Evofem Biosciences and Aditxt have amended their merger agreement for a second time, pushing back the loan date and the proxy statement filing date.

Evofem Biosciences has filed an amendment to its previous 8-K report to correct a link to the Certificate of Designation of the Series F-1 Preferred Stock related to its merger with Aditxt, Inc.

Evofem Biosciences and Aditxt have amended their merger agreement, pushing the filing date for the joint proxy statement to February 14, 2024.